Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium
- PMID: 20587123
- DOI: 10.1017/S0950268810001536
Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium
Abstract
Susceptibility to vaccine-preventable diseases in Belgium in 2006 was estimated from a serum survey. Immunoglobulins against measles, mumps, rubella (MMR) and diphtheria at all available ages (1-65 years), and against tetanus in >40-year-olds, were measured by ELISA. Age-standardized overall seronegativity for MMR was low (3·9%, 8·0%, 10·4%, respectively). However, the World Health Organization's targets for measles elimination were not met in 5- to 24-year-olds and about 1 in 7 women at childbearing age (15-39 years) were seronegative for rubella. In adults >40 years, tetanus immunity (87·2%, >0·16 IU/ml) largely exceeded diphtheria immunity (20-45%, >0·1 IU/ml). Despite free universal vaccination against MMR for more than 20 years and against diphtheria and tetanus for almost 60 years, our study revealed specific age groups remaining at risk for infection with these pathogens.
Similar articles
-
Seroprevalences of antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella: A cross-sectional study in children following vaccination procedure in Guangzhou, China.Vaccine. 2020 May 13;38(23):3960-3967. doi: 10.1016/j.vaccine.2020.03.056. Epub 2020 Apr 19. Vaccine. 2020. PMID: 32321685
-
[Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].Schweiz Med Wochenschr. 1998 Apr 25;128(17):649-57. Schweiz Med Wochenschr. 1998. PMID: 9622837 German.
-
Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.Ann Rheum Dis. 2012 Jun;71(6):948-54. doi: 10.1136/annrheumdis-2011-200637. Epub 2011 Dec 15. Ann Rheum Dis. 2012. PMID: 22172491
-
When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?Vaccine. 2012 Sep 7;30 Suppl 3:C58-60. doi: 10.1016/j.vaccine.2012.02.082. Vaccine. 2012. PMID: 22939023 Review.
-
The control of diphtheria, tetanus, poliomyelitis, measles, rubella and mumps.Practitioner. 1975 Sep;215(1287):299-309. Practitioner. 1975. PMID: 1101251 Review. No abstract available.
Cited by
-
Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.Hum Vaccin Immunother. 2013 Sep;9(9):1918-25. doi: 10.4161/hv.25127. Epub 2013 Jun 21. Hum Vaccin Immunother. 2013. PMID: 23793571 Free PMC article.
-
Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China.Hum Vaccin Immunother. 2021 Jun 3;17(6):1757-1762. doi: 10.1080/21645515.2020.1840253. Epub 2021 Jan 30. Hum Vaccin Immunother. 2021. PMID: 33517831 Free PMC article.
-
Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.BMC Med. 2019 Sep 25;17(1):180. doi: 10.1186/s12916-019-1413-7. BMC Med. 2019. PMID: 31551070 Free PMC article.
-
Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).Lancet Reg Health Eur. 2021 Jun 5;7:100128. doi: 10.1016/j.lanepe.2021.100128. eCollection 2021 Aug. Lancet Reg Health Eur. 2021. PMID: 34557838 Free PMC article.
-
Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.PLoS One. 2012;7(8):e42867. doi: 10.1371/journal.pone.0042867. Epub 2012 Aug 6. PLoS One. 2012. PMID: 22880124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous